334 related articles for article (PubMed ID: 17700364)
1. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
[TBL] [Abstract][Full Text] [Related]
2. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
Tarr PE; Taffé P; Bleiber G; Furrer H; Rotger M; Martinez R; Hirschel B; Battegay M; Weber R; Vernazza P; Bernasconi E; Darioli R; Rickenbach M; Ledergerber B; Telenti A;
J Infect Dis; 2005 May; 191(9):1419-26. PubMed ID: 15809899
[TBL] [Abstract][Full Text] [Related]
3. Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy.
Bautista-Martínez JS; Mata-Marín JA; Sandoval-Ramírez JL; Chaparro-Sánchez A; Manjarrez-Téllez B; Uribe-Noguez LA; Gaytán-Martínez J; Núñez-Armendáriz M; Cruz-Sánchez A; Núñez-Rodríguez N; Iván MA; Morales-González GS; Álvarez-Mendoza JP; Pérez-Barragán E; Ríos-De Los Ríos J; Contreras-Chávez GG; Tapia-Magallanes DM; Ribas-Aparicio RM; Díaz-López M; Olivares-Labastida A; Gómez-Delgado A; Torres J; Miranda-Duarte A; Zenteno JC; Pompa-Mera EN
Pharmacogenet Genomics; 2022 Apr; 32(3):101-110. PubMed ID: 34693928
[TBL] [Abstract][Full Text] [Related]
4. [Genetic determination of dyslipidemia - What tell us the results of genome-wide association studies?].
Hubáček JA
Vnitr Lek; 2016; 62(11):868-876. PubMed ID: 28128572
[TBL] [Abstract][Full Text] [Related]
5. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE;
Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner.
Guardiola M; Echeverria P; González M; Vallvé JC; Puig J; Clotet B; Ribalta J; Negredo E
AIDS Res Hum Retroviruses; 2015 Sep; 31(9):882-8. PubMed ID: 26101956
[TBL] [Abstract][Full Text] [Related]
7. APOE, CETP and LPL genes show strong association with lipid levels in Greek children.
Smart MC; Dedoussis G; Louizou E; Yannakoulia M; Drenos F; Papoutsakis C; Maniatis N; Humphries SE; Talmud PJ
Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):26-33. PubMed ID: 19403283
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
Egaña-Gorroño L; Martínez E; Cormand B; Escribà T; Gatell J; Arnedo M
AIDS; 2013 Feb; 27(4):529-38. PubMed ID: 23262498
[TBL] [Abstract][Full Text] [Related]
9. Is dyslipidemia sustained during remission of nephrotic syndrome genetically determined? Evaluation of genetic polymorphisms of proteins involved in lipoprotein metabolism in children and adolescents with nephrotic syndrome.
Ksiazek J; Ciechanowicz A; Wierzbicka A; Syczewska M; Grenda R
Pol Arch Med Wewn; 2009; 119(1-2):11-6. PubMed ID: 19341173
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients.
Echeverria P; Guardiola M; González M; Vallvé JC; Bonjoch A; Puig J; Clotet B; Ribalta J; Negredo E
Antiviral Res; 2015 Feb; 114():48-52. PubMed ID: 25500319
[TBL] [Abstract][Full Text] [Related]
11. Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome.
Stancáková A; Baldaufová L; Javorský M; Kozárová M; Salagovic J; Tkác I
Physiol Res; 2006; 55(5):483-490. PubMed ID: 16343038
[TBL] [Abstract][Full Text] [Related]
12. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
13. Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.
Villard EF; EI Khoury P; Frisdal E; Bruckert E; Clement K; Bonnefont-Rousselot D; Bittar R; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):822-8. PubMed ID: 23372063
[TBL] [Abstract][Full Text] [Related]
14. Prediction of genetic risk for dyslipidemia.
Yamada Y; Matsuo H; Warita S; Watanabe S; Kato K; Oguri M; Yokoi K; Metoki N; Yoshida H; Satoh K; Ichihara S; Aoyagi Y; Yasunaga A; Park H; Tanaka M; Nozawa Y
Genomics; 2007 Nov; 90(5):551-8. PubMed ID: 17919884
[TBL] [Abstract][Full Text] [Related]
15. Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study.
Obirikorang C; Acheampong E; Quaye L; Yorke J; Amos-Abanyie EK; Akyaw PA; Anto EO; Bani SB; Asamoah EA; Batu EN
PLoS One; 2020; 15(1):e0227779. PubMed ID: 31929604
[TBL] [Abstract][Full Text] [Related]
16. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.
Tarr PE; Rotger M; Telenti A
Pharmacogenomics; 2010 Apr; 11(4):587-94. PubMed ID: 20350140
[TBL] [Abstract][Full Text] [Related]
17. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).
Raj R; Bhatti JS; Badada SK; Ramteke PW
Diabetes Metab Res Rev; 2015 Oct; 31(7):663-71. PubMed ID: 25470794
[TBL] [Abstract][Full Text] [Related]
18. Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.
Lamon-Fava S; Asztalos BF; Howard TD; Reboussin DM; Horvath KV; Schaefer EJ; Herrington DM
Clin Endocrinol (Oxf); 2010 Feb; 72(2):169-75. PubMed ID: 19489872
[TBL] [Abstract][Full Text] [Related]
19. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults.
Komurcu-Bayrak E; Onat A; Poda M; Humphries SE; Palmen J; Guclu F; Can G; Erginel-Unaltuna N
Clin Chem Lab Med; 2008; 46(6):778-84. PubMed ID: 18601598
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents.
Brito DD; Fernandes AP; Gomes KB; Coelho FF; Cruz NG; Sabino AP; Cardoso JE; Figueiredo-Filho PP; Diamante R; Norton CR; Sousa MO
Mol Biol Rep; 2011 Oct; 38(7):4381-8. PubMed ID: 21132386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
